Production of mRNA by in vitro transcription utilizing a single-use system

Nucleic Acid Insights 2024; 1(4), 1

DOI: 10.18609/nai.2023.001

Published: 15 May
David Sokolowski

Watch the video or view the poster for insights on:

  • The importance of the in vitro transcription (IVT) process in the mRNA manufacturing workflow
  • Ensuring stability of mRNA, minimizing undesirable truncated or double-stranded products, and allowing for successful scale-up
  • An overview of how single-use technology can help reduce RNAse contamination in IVT
  • Case study data on generating high quality RNA with the WAVE 25 bioreactor

David is an experienced biopharma professional with many years of industry experience. Dave joined PALL Corporation as an R&D engineer supporting the development of acoustic technologies, before moving into Project Management, and then into Global Product Management. He is an integral part of the cross-functional nucleic acids and nanomedicine teams within Cytiva, created to support mRNA workflows. Prior to his professional career, he acquired a B.S. in Microbiology from the University of Massachusetts, Amherst, which inspired him to join the UMass Med School PhD program investigating the post-transcriptional regulation of mRNA through RNA-binding protein interactions. Prior to completing his PhD, Dave chose to refocus his career towards scientific technology application development, and instead earned a B.S. in Mechanical Engineering from UMass Amherst.